• LAST PRICE
    3.1200
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    2.9500/ 1
  • Ask / Lots
    4.0000/ 60
  • Open / Previous Close
    3.2800 / 3.1200
  • Day Range
    Low 3.0700
    High 3.3400
  • 52 Week Range
    Low 2.0200
    High 5.2900
  • Volume
    11,134
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 3.35
TimeVolumeMIRO
09:32 ET6383.28
09:57 ET1003.34
10:08 ET1003.3396
10:09 ET1003.315
10:15 ET4003.3
10:24 ET1003.3
10:44 ET2013.3
10:51 ET4003.3
10:54 ET2003.3
11:52 ET1003.29
11:54 ET3503.3
12:06 ET1003.3
12:53 ET2003.3
01:54 ET2003.3
02:03 ET1003.3
02:07 ET1003.3
02:54 ET2003.3
03:12 ET1003.3
03:14 ET1003.2801
03:15 ET4003.28
03:17 ET7003.27
03:19 ET1003.2
03:21 ET4973.21
03:26 ET1003.2
03:28 ET2003.2
03:30 ET4533.17
03:37 ET1003.17
03:44 ET2023.15
03:48 ET1003.15
03:50 ET3003.15
03:53 ET1003.17
03:55 ET7253.15
03:57 ET1453.07
04:00 ET5893.12
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesMIRO
Miromatrix Medical Inc
65.2M
-2.3x
---
United StatesIMNM
Immunome Inc
64.9M
-1.7x
---
United StatesHCWB
HCW Biologics Inc
66.0M
-5.2x
---
United StatesGRTX
Galera Therapeutics Inc
64.4M
-1.0x
---
United StatesAPTO
Aptose Biosciences Inc
63.8M
-1.1x
---
United StatesCADL
Candel Therapeutics Inc
66.7M
-5.5x
---
As of 2023-02-09

Company Information

Miromatrix Medical Inc. a life sciences company. The Company is engaged in providing the technology for bioengineering fully transplantable human organs to help save and improve patients' lives. The Company’s technology platform uses a two-step method of decellularization and recellularization. Its development focus is on bioengineering livers and kidneys, and its technology platform is also applicable to bioengineering other organs, including hearts, lungs, and pancreases. Decellularization is a process that is designed to remove porcine cells from the organs obtained from pigs to create a purified acellular extracellular matrix (ECM). Its perfusion process purifies the organs while preserving the mechanical structures and vascular networks. Recellularization is a process that incorporates perfusion to re-seed the ECM with unmodified human cells inside individual bioreactors. The Company's product pipeline includes miroliver, mirokidney, miroheart, mirolung and miropancreas.

Contact Information

Headquarters
6455 Flying Cloud Drive, Suite 107EDEN PRAIRIE, MN, United States 55344
Phone
612-202-7026
Fax
302-655-5049

Executives

Independent Chairman of the Board
Paul Buckman
Chief Executive Officer, Director
Jeffrey Ross
Chief Financial Officer, Secretary
James Douglas
Vice President - Quality
Laji Kattungal
Vice President - Research & Development
John Barry

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$65.2M
Revenue (TTM)
$31.1K
Shares Outstanding
20.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-1.38
Book Value
$2.66
P/E Ratio
-2.3x
Price/Sales (TTM)
2,095.8
Price/Cash Flow (TTM)
---
Operating Margin
-92,039.49%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.